New perspectives in the therapy of castration resistant prostate cancer

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1676-1686

  Rescigno, Pasquale ^a   Buonerba, Carlo ^a   Bellmunt, Joaquim ^b   Sonpavde, Guru ^c   de Placido, Sabino ^a   Di Lorenzo, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chemotherapy; Hormonal therapy; Immunotherapy and targeted therapy; Metastatic castration resistant prostate cancer

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DASATINIB; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; GALETERONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; MINALRESTAT; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; EDEMA; FATIGUE; FEVER; FLUID RETENTION; HEADACHE; HOT FLUSH; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOPITUITARISM; LEUKOPENIA; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TAXOIDS;

EID: 84870165370     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803529956     Document Type: Article

References (66)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62(4): 220-241.
2. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367 (7): 595-605.
3. Di Lorenzo G, Buonerba C, Autorino R, et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70 (8): 983-1000.
4. Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012; 30 (6): 644-646.
5. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011; 8 (9): 551-561.
6. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12): 2298-2308.
7. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995-2005.
8. Scher HI, Fizazi K, Saad F, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
9. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010; 376 (9747): 1147-1154.
10. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-422.
11. Parker C, Heinrich D, O'Sullivan JM, et al. Phase III trial of alpharadin (radium-223) for metastatic castration-resistant prostate cancer with bone metastases. Presented at 2011 European Society Medical Oncology (ESMO) Congress; September 23-27, 2011; Stockholm, Sweden. Abstract n. 1LBA.
12. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26(7): 1148-1159.
13. Huggins C, Hodges CV. Studies on prostate cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22 (4): 232-240.
14. Huggins C, Hodges CV. Studies on prostate cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 2002; 167 (2): 948-951.
15. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20 (13): 3001-3015.
16. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261.
17. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15 (4): 841-849.
18. Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist 2006; 11(5): 451-462.
19. Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int 2012; 110(2 Pt 2): E99-E104.
20. Petrylak DP, Dawson NA, Gardner T, et al. Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15 suppl (May 20 Supplement), 2010: abstract: 4551.
21. U.S. Food and Drug Administration. U.S. FDA Approves First Cancer Vaccine. [accessed August 3, 2012]. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm.
22. Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther 2012; 12 (4): 463-478.
23. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28 (7): 1099-1105.
24. Trinh VA, Hwu WJ. Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther 2012; 12 (6): 773-782.
25. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69 (2): 609-615.
26. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colonystimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13 (5): 509-517.
27. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13(5): 501-508.
28. Villanueva C, Bazan F, Kim S, et al. Cabazitaxel: a novel microtubule inhibitor. Drugs 2011; 71(10): 1251-1258.
29. Bedoya DJ, Mitsiades N. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration- resistant prostate cancer. Expert Rev Anticancer Ther 2012; 12(1): 1-3.
30. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2012, ASCO Annual Meeting, J Clin Oncol 30, 2012 (suppl; abstr LBA4518.
31. Tran C, Ouk S, Clegg NJ et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 2009; 324(5928): 787-790.
32. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1-2 study. Lancet 2010; 375(9724): 1437-1446.
33. Enzalutamide (XTANDICapsules). Available at http://www.fda.gov/Drugs/InformationOnDrugs/Approved-Drugs/ucm317997.htm. Accessed on 15th September 2012.
34. Yamaoka M, Hara T, Hitaka T, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 2012; 129(3-5): 115-128.
35. Drecier R, Angus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. ASCO Genitourin Cancer Symp Proc 2010; 89: abstract 103.
36. Montgomery B, Eisenberger MA, Rettig M, et al. Phase 1 clinical trial of galeterone (TOK-001) a multifunctional antiandrogen and CYP17 inhibitor in Castration Resistant Prostate Cancer (CRPC). 2012, Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, US, Abstract 4665.
37. Taplin M, Chu F, Morrison JP, et al. ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration-resistant prostate cancer (CRPC). AACR 103rd Annual Meeting 2012, Mar 31-Apr 4, 2012; Chicago, Abstract CT-07.
38. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72(6): 1494-1503.
39. Rathkopf DE, Danila DC, Morris MJ, et al. Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study. ASCO Annual meeting 2012, Chicago, US. J Clin Oncol 30, 2012 (suppl 5; abstr 43)
40. Tu WH, Zhu C, Clark C, et al. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010; 10: 556.
41. Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 2012; 12 (1): 198.
42. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29(19): 2660-2666.
43. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29(suppl). Abstract 4516 and oral presentation at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL.
44. Pili R, Häggman M, Stadler WM, et al. Phase II randomized, double- blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29 (30): 4022-4028.
45. Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a secondgeneration antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 2008; 17(12): 1955-1962.
46. Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res 2009; 105: 77-92.
47. Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997; 3(10): 1707-1711.
48. Chi KN, Hotte SJ, Yu EY, et al. A randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28 (27): 4247-4254.
49. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65 (20): 9185-9189.
50. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15 (23): 7421-7128.
51. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration resistant prostate cancer: results from a phase 1-2study. Cancer 2012; 118 (1): 63-71.
52. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer- induced bone diseases. Cancer Metastasis Rev 2006; 25(4): 541-549.
53. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration- resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768): 813-822.
54. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27(7): 1471-1479.
55. Smith MR, Saad F, Coleman R, Denosumab and bone-metastasisfree survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379(9810): 39-46.
56. FDA rejects Amgen's application for Xgeva. Available at http://www.reuters.com/article/2012/04/27/us-amgenidUSBRE83Q05M20120427. Accessed 15th August 2012.
57. Xgeva® (denosumab) FDA labeling Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf
58. Cheetham PJ, Petrylak DP. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium- 223 chloride (Alpharadin) and radiation protection. Oncology 2012; 26(4): 330-337, 341.
59. Sartor AO, Heinrich D, Helle SI, et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA). ASCO Annual Meeting 2012, Chicago, US. J Clin Oncol 30, 2012 (suppl 5; abstr 9).
60. http://www.press.bayer.com/baynews/baynews.nsf/id/Positive-Phase-III-Data-Bayers-Investigational-Drug-Alpharadin-Show-Significant-Increase-Overall. Accessed 15th September 2012.
61. Malgieri S, Feliciano S, Bosso D, et al. Non-small cell lung cancer: from targeted therapy to tailored therapy. Expert Opin Pharmacother 2012; 13: 1817-1819.
62. Di Lorenzo G, De Placido S, Buonerba C. Second-line treatment for renal cell cancer. Br J Cancer 2012; 106(4): 617-618.
63. Ryan C, Li J, Kheoh T, et al. Abstract LB-434: Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Results of the COU-AA-301 phase 3 randomized trial. Proceedings: AACR 103rd Annual Meeting 2012; Mar 31- Apr 4, 2012; Chicago, IL. Cancer Res 2012; 72(8 Suppl): Abstract n LB-434.
64. Zhang X, Morrissey C, Sun S, Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011; 6(11): e27970.
65. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44(6): 685-689. http://www.ncbi.nlm.nih.gov/pubmed?term=BuonerbaC%5BAuthor%5D&cauthor=true&cauthor_uid=21166508
66. Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther 2011; 11: 25-28.